Cognitive function in schizophrenia - Do neuroleptics make a difference?

Pharmacology Biochemistry and Behavior

Volumn 56, Issue 4, 1997, Pages 789-795

  Mortimer, Ann M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

arousal; clozapine; cognition; neuroleptics, atypical; reticular activating system; schizophrenia

Indexed keywords

AMPHETAMINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; THIORIDAZINE;

ANIMAL MODEL; AROUSAL; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEMORY; MONOAMINERGIC SYSTEM; MOTIVATION; NEUROPHYSIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOLOGY; RECEPTOR BLOCKING; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANIMALIA;

EID: 0030972350     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00425-X     Document Type: Article

References (74)

1. Andreasen N. C., Resai K., Alliger R., Swayze V. W., Flaum M., Kirchner P., Cohen G., O'Leary D. S. Hypofrontality in neuroleptic naive patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 49:1992;943-958.
2. Bilder R. M., Lieberman J. A., Kim Y., Alvir J., Reiter G. Methylphenidate and neuroleptic effects on oral word production in schizophrenia. Neuropsychiatry Neuropsychol. Behav. Neurol. 5:1992;262-271.
3. Bilder R. M., Lipshutz-Broch L., Reiter G., Geisler S. H., Mayerhoff D. I., Lieberman J. A. Intellectual deficits in first-episode schizophrenia. Evidence for progressive deterioration? Schizophr. Bull. 18:1992;437-448.
4. Bornstein H. A., Nasrallah H. A., Olson S. C., Coffman J. A., Torello M., Schwarzkopf S. B. Neuropsychological deficit in schizophrenic subtypes. Paranoid, nonparanoid and schizoaffective subgroups Psychiatr. Res. 31:1990;15-24.
5. Broadbent D. E. Performance and its measurement. Br. J. Clin. Pharmacol. 18:1984;5S-9S.
6. Buchanan R. W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36:1994;717-725.
7. Cantor-Graae E., Warkentin S., Nilsson A. Neuropsychological assment of schizophrenic patients during a psychotic episode. Persistent cognitive deficit? Acta Psychiatr. Scand. 91:1995;283-288.
8. Carpenter W. T., Buchanan J. R., Buchanan R. W. Domains of psychopathology relevant to the study of etiology and treatment in schizophrenia. Schulz S. C., Tamminga C. A. Schizophrenia. Scientific progress:1989;Oxford University Press, Oxford, UK.
9. Cassens G., Inglis A. K., Appelbaum P. S., Gotheil T. G. Neuroleptics. Effects on neuropsychological function in chronic schizophrenic patients Schizophr. Bull. 16:1990;477-499.
10. Clare L., McKenna P. J., Mortimer A. M., Baddeley A. D. Memory in schizophrenia. What is impaired and what is preserved? Neuropsychologia. 31:1993;1225-1241.
11. Classen W., Laux G. Sensorimotor and cognitive performance of schizophrenic patients treated with haloperodol, flupenthixol, or clozapine. Pharmacopsychiatry. 21:1988;295-297.
12. Cleghorn J. M., Kaplan R. D., Szechtman B., Szetchman H., Brown G. M. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr. Res. 3:1990;211-219.
13. Daniel D. G. Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders. Biol. Psychiatry. 35:1994;667. Abstr.
14. Davidson M., Haroutunian V. Cognitive impairment in geriatric schizophrenic patients. Clinical and postmortem characterization Bloom F. E., Kupfer D. J. Psychopharmacology. The fourth generation of progress:1996;Raven Press, New York.
15. Davidson M., Keefe R. S. E. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr. Res. 17:1995;123-129.
16. Deutch A. Y. Mechanisms of action of clozapine in the treatment of neuroleptic-resistant and neuroleptic-intolerant schizophrenia. Eur. Psychiatry. 10:1995;39s-46s.
17. Duffy L., O'Carroll R. Memory impairment in schizophrenia - A comparison with that observed in the alcoholic Korsakoff syndrome. Psychol. Med. 24:1994;155-166.
18. Dye S., Mortimer A. M. Clozapine and the neuropsychology of schizophrenia. Eur. Psychiatry. 11:1996;279s.
19. Frith C. D. The cognitive neuropsychology of schizophrenia. 1992;Lawrence Erlbaum, Hove, Sussex, UK.
20. Frith C. D., Done D. J. Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action. Psychol. Med. 19:1989;359-363.
21. Frith C. D., Leary J., Cahill C., Johnstone E. C. Performance on psychological tests. Demographic and clinical correlates of the results of these tests Br. J. Psychiatry. 159:1991;26-29.
22. Goldberg E. Akinesia, tardive dysmentia, and frontal lobe disorders in schizophrenia. Schizophr. Bull. 11:1995;255-263.
23. Goldberg T. E., Gold J. M., Greenberg R., Griffin S., Schulz S. C., Pickar D., Kleinman J. E., Weinberger D. R. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am. J. Psychiatry. 150:1993;1355-1362.
24. Goldberg T. E., Greenberg R. D., Griffin S. J. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 162:1993;43-48.
25. Goldberg T. E., Hyde T. M., Kleinman J. E., Weinberger D. R. Course of schizophrenia. Neuropsychological evidence for a static encephalopathy Schizophr. Bull. 19:1993;797-804.
26. Goldberg T. E., Torrey E. F., Gold J. M., Ragland J. D., Bigelow L. D., Weinberger D. R. Learning and memory in monozygotic twins discordant for schizophrenia. Psychol. Med. 23:1993;71-85.
27. Goldberg T. E., Weinberger D. R. The effects of clozapine on neurocognition. An overview J. Clin. Psychiatry. 55:1994;88-90.
28. Goldberg T. E., Weinberger D. R. Thought disorder, working memory and attention. Interrelationships and the effects of neuroleptic medications Int. Clin. Psychopharmacol. 10:1995;99-104.
29. Goldberg T. E., Weinberger D. R., Berman K. F., Plisken N., Podd M. H. Further evidence for dementia of prefrontal type in schizophrenia? Arch. Gen. Psychiatry. 44:1987;1008-1014.
30. Green M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153:1996;321-330.
31. Hagger C., Buckley P., Kenny J. T., Friedman L., Ubogy D., Meltzer H. Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
32. Heaton R. K., Baade L. E., Johnson K. L. Neuropsychological test patterns associated with psychiatric disorders in adults. Psychol. Bull. 85:1978;146-162.
33. Heaton R. K., Crowley T. J. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. Filskov S. D., Boll T. J. Handbook of clinical neuropsychology. 1981;John Wiley & Sons, New York.
34. Heaton R. K., Paulsen J. S., McAdams L. A. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity and dementia. Arch. Gen. Psychiatry. 51:1994;469-476.
35. Hindmarch I., Tiplady B. A comparison of the psychometric effects of remoxipride with those of haloperidol, thioridazine and lorazepam in healthy volunteers. Hum. Psychopharmacol. 9:1994;43-49.
36. Hoff A. L., Riordan H., O'Donnell D. W., Morris L., De Lisi L. E. Neuropsychological functioning of first-episode schizophreniform patients. Am. J. Psychiatry. 149:1992;898-903.
37. Hoff, A. L.; Weineke, M.; DeVilliers, D.: Effects of clozapine on cognitive function. 124; 1993. [Abstr.].
38. Humphries, C.; Mortimer, A. M.; Hirsch, S. R.; de Belleroche, J.: NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. NeuroReport; 1996, in press.
39. Hyde T. M., Nawroz S., Goldberg T. E. Is there cognitive decline in schizophrenia? A cross-sectional study. Br. J. Psychiatry. 164:1994;494-500.
40. Kaufman C. A., Weinberger D. R. The neurobiological basis of psychiatric disability. Meyerson A. T., Fine T. Psychiatric disability. Clinical, legal and administrative dimensions:1987;American Psychiatric Press, Washington, DC.
41. Kerwin R. W. The new atypical antipsychotics. Br. J. Psychiatry. 164:1994;141-148.
42. King D. J. The effect of neuroleptics on cognitive and psychomotor function. Br. J. Psychiatry. 157:1990;799-811.
43. King D. J., Henry G. The effect of neuroleptics on cognitive and psychomotor function, a preliminary study in healthy volunteers. Br. J. Psychiatry. 160:1992;647-653.
44. Kolb B., Whishaw I. Q. Performance of schizophrenic patients on tests sensitive to right or left frontal, temporal or parietal function in neurological patients. J. Nerv. Ment. Dis. 171:1983;435-443.
45. Lewis S. W., Ford R. A., Syed G. M., Reveley A. M., Toone B. K. A controlled study of 99mTc-HMPAO single photon emission imaging in chronic schizophrenia. Psychol. Med. 22:1992;27-35.
46. Liddle P. F., Crow T. J. Age disorientation in chronic schizophrenia is associated with global intellectual impairment. Br. J. Psychiatry. 144:1984;193-199.
47. Liddle P. F., Morris D. L. Schizophrenic syndromes and frontal lobe performance. Br. J. Psychiatry. 158:1991;340-345.
48. McKay A. P., McKenna P. J., Bentham P., Mortimer A. M., Holbery A., Hodges J. R. Semantic memory is impaired in schizophrenia. Biol. Psychiatry. 39:1996;929-937.
49. Medalia A., Gold J. M., Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch. Clin. Neuropsychol. 3:1988;249-271.
50. Meltzer H. Y. Dimensions of outcome with clozapine. Br. J. Psychiatry. 160:1992;46-53.
51. Mlakar J., Jensterle J., Frith C. D. Central monitoring deficiency and schizophrenic symptoms. Psychol. Med. 24:1994;557-564.
52. Morice R. Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br. J. Psychiatry. 157:1990;50-54.
53. Mortimer A. M. Clozapine and schizophrenia. Schizophr. Monit. 1:1991;1-4.
54. Mortimer A. M., McKenna P. J. Levels of explanation - Symptoms, neuropsychological deficit and morphological abnormalities in schizophrenia. Br. J. Psychiatry. 24:1994;541-545.
55. Nelson H. E., Pantelis C., Carruthers K., Speller J., Baxendale S., Barnes T. R. E. Cognitive functioning and symptomatology in chronic schizophrenia. Psychol. Med. 20:1990;357-365.
56. Owens D. G. C., Johnstone E. C. The disabilities of chronic schizophrenia. Their nature and the factors contributing to their development Br. J. Psychiatry. 136:1980;384-393.
57. Pigache R. M. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlopromazine. Schizophr. Res. 10:1993;39-50.
58. Plisken N., Raz N., Raz S., Weinberger D. R. Neuroleptic withdrawal and deterioration of verbal fluency in schizophrenia. A preliminary report J. Clin. Exp. Neuropsychol. 9:1987;62.
59. Purohit D. P., Davidson M., Perl D. P., Powchik P., Haroutunian V., Bierer L. M., McCrystal J., Losonczy M., Davis K. L. Severe cognitive impairment in elderly schizophrenic patients. A clinicopathological study Biol. Psychiatry. 33:1993;255-260.
60. Riddle M., Roberts A. H. Psychosurgery and the Porteus maze tests. Arch. Gen. Psychiatry. 35:1978;493-497.
61. Robbins T. W., Everitt B. J. Arousal systems and attention. Gazzaniga M. The cognitive neurosciences. 1995;703-720 MIT Press, Cambridge, MA.
62. Saletu B., Grunberger J., Linzmayer L. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Pharmacopsychiatry. 20:1987;12-27.
63. Saykin A. J., Shtasel D. L., Gur R. E., Kester D. B., Mozley L. H., Stafiniak P., Gur R. C. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry. 51:1994;124-131.
64. Seidman L. J., Pepple J. R., Faraone S. V. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol. Psychiatry. 33:1993;575-584.
65. Shallice T., Burgess P., Frith C. D. Can the neuropsychological case study be applied to schizophrenia? Psychol. Med. 21:1991;661-673.
66. Spohn H. E., Strauss M. E. Relation of neuroleptic and anticholinergic medications to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98:1989;367-380.
67. Sweeney J. A., Haas G. L., Keilp J. G., Long M. Evaluation of neuropsychological function after acute episodes of schizophrenia. One-year followup study Psychiatr. Res. 38:1991;63-76.
68. Tamlyn D., McKenna P. J., Mortimer A. M., Lund C. E., Hammond S., Baddeley A. D. Memory impairment in schizophrenia. Its extent, affiliations and neuropsychological character Psychol. Med. 22:1992;101-115.
69. Van Praag H. M., Asnis G. M., Kahn R. S. Monoamines and abnormal behaviour. A multi-aminergic perspective. Br. J. Psychiatry. 157:1990;723-734.
70. Verdoux H., Magnin E., Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophr. Res. 14:1995;133-139.
71. Waddington J. L., Scully P. J., Coakley G., Kinsella A. Course of illness in schizophrenia in relation to duration of initially untreated psychosis. Eur. Neuropsychopharmacol. 6(suppl. 4):1996;S4-S31.
72. Weinberger D. R., Berman K. F., Zec R. F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Arch. Gen. Psychiatry. 43:1986;114-124.
73. Gerlach J., Peacock L. New antipsychotics. The present status Int. Clin. Psychopharmacol. 10(suppl. 3):1995;39-48.
74. McGrath J. Ordering thoughts on thought disorder. Br. J. Psychiatry. 158:1991;307-316.